Abstract The development of cancer reflects the complex interactions and properties of many proteins functioning as part of large biochemical networks within the cancer cell. Although traditional experimental models have provided us with wonderful insights on the behavior of individual proteins within a cancer cell, they have been deficient in simultaneously keeping track of many proteins and their interactions in large networks. Computational models have emerged as a powerful tool for investigating biochemical networks due to their ability to meaningfully assimilate numerous network properties. Using the well-studied Ras oncogene as an example, we discuss the use of models to investigate pathologic Ras signaling and describe how these models could play a role in the development of new cancer drugs and the design of individualized treatment regimens.
The Ras Signaling Module
Ras is a small GTPase that functions as a cell signaling protein (19) . It is downstream of many receptor tyrosine kinases associated with cancer (e.g., epidermal growth factor receptor) and upstream of many signaling pathways associated with cancer (e.g., Raf/Mek/Erk, PI3K/PTEN/Akt). Ras cycles between GTP-and GDP-bound states, each of which adopts a different structural conformation (20) . Signaling proteins that interact with Ras (e.g., Raf, PI3K, RalGDS) have domains that bind the GTP-bound conformation of Ras (RasGTP) with a much higher affinity than the GDP-bound conformation of Ras (RasGDP; ref. 21) . Three RAS genes encode four Ras protein products (H-Ras, N-Ras, K-RasA, K-RasB), and mutant forms of any of these genes that result in an increased fraction of RasGTP can be found in many different cancers, with K-Ras being the most commonly mutated Ras isoform found in most cancers (19) . Efforts to inhibit Ras signaling directly have been most focused on inhibiting the enzymes involved with the posttranslational processing of Ras, most notably with farnesyltransferase inhibitors (22) . Although these drugs seem to inhibit Ras processing in vitro (23, 24) and in vivo (25), they have not proven as useful clinically as had been hoped.
The amount of RasGTP in a cell reflects many different processes that influence the nucleotide binding state of Ras (Fig. 1) . Ras has GTPase activity and can hydrolyze GTP, thus converting RasGTP to RasGDP (26) . Guanine nucleotides can freely dissociate from Ras and associate with Ras, allowing interconversion between RasGDP and RasGTP (26, 27) . GTPase activating proteins (GAP) and Guanine nucleotide exchange factors (GEF) are enzymes that catalyze the nucleotide hydrolysis and exchange reactions, respectively (27, 28) . The modulation of GEFs and GAPs is believed to be the major (28); (ii) GAP-mediated GTP hydrolysis seems to be eliminated (32); (iii) some isoforms may have higher affinity for downstream signaling proteins (33) .
Modeling the Ras Network
Although the biochemical characterization of the different reactions that collectively regulate Ras has greatly affected our understanding of how Ras signaling is deregulated in disease, a full use of this detailed biochemical information has been limited by the scope and the complexity of Ras regulation. Mathematical models are less restricted by scope and can simultaneously manage multiple biochemical reactions, their numerous different rate constants, and the varying molecular concentrations (6) . Many mathematical models have studied signaling networks that include wild-type Ras (10, 11, 14 -18) and some have used models of Ras regulation to investigate how changes in rate constants that occur with oncogenic Ras mutation might influence Ras activity (10, 26, 34) . However, modeling requires the making of simplifications, and simplifications to the complex regulation of Ras have been noted previously as a common feature of many models (35) . Although a model may include some sort of representation of Ras, that model may not be well-suited for investigating questions focused on Ras biology. We therefore set out to develop a model for investigating Ras that included each of the different classes of processes that regulate Ras signaling and the rate constants and other quantitative parameters that characterize these reactions, specifically incorporating both wild-type and mutant Ras in the same system. We have then attempted to link the known biochemical changes with observed patterns of Ras activation in the context of mutant Ras and to use this model to investigate problems in oncogenic Ras biology (12) .
Our model included the fast (GEF and GAP mediated) and slow (Ras GTPase and nucleotide dissociation and association) reactions, effector interactions, as well as both wild-type and mutant Ras proteins. The model uses the accepted network connectivity, published rate constants, and rate constants that had not yet been measured were calculated to be consistent with published experimental data. Our model's predictions for the fraction of Ras bound to GTP matched well with experimental data for several different situations. Investigation into why only one of two classes of Ras mutants with in vitro Fig. 1 . The Ras signaling module. The Ras GTPase binds nucleotides GTP and GDP. Ras effectors specifically bind the GTP bound form of Ras, which is considered to be the signaling competent form of Ras (A). GEFs facilitate the exchange of bound nucleotide (B). GAPs facilitate GTP hydrolysis (C). Additionally, Ras has slow intrinsic GTPase activity, allowing for some conversion of GTP to GDP (D). Nucleotide association and dissociation can also occur without the aid of GEFs (E). The amount of RasGTP in the cell reflects the actions of all of these processes. The Ras mutants associated with cancer are subject to these same reactions, although with some major differences. For example, GAP-insensitive Ras mutants (such as RasG12V) bind to GAP but the GTPase reaction is not increased by the GAP. These differences are reflected by the different values to the rate constants and parameters that characterize these reactions. In a cell with both wild-type and mutant Ras, the total amount of RasGTP reflects the action of these processes on both wild-type and mutant Ras, as well as the interactions with both Ras forms on the other proteins in the network.
transformation potential is commonly found in cancer resulted in a new prediction about how the specific biochemical changes relate to the intensity of Ras signal, and this predicted pattern of activation was experimentally confirmed (12) . Model simulations and subsequent experiments also found that the competitive inhibition of Ras GAPs by oncogenic Ras mutants results in decreased Ras GAP activity on wild-type Ras and leads to an increase in wild-type RasGTP. The contribution of this ''systems level'' process to total Ras signal in the context of mutant Ras was likely overlooked for reasons that include the difficulty of simultaneously considering the many different processes regulating Ras signals, and also the difficulty of considering how these processes depend upon their quantitative variables.
Clinical-Translational Advances
Benefits of modeling. It has been argued that drug development needs to be more systems-oriented experimentally (36) , and computational models should also be able to play a role in systems-oriented drug development (37, 38) . Along these lines, our work investigated the reduction of total RasGTP that would result from reversing one of the three biochemical defects of oncogenic Ras. The computational analysis found that as long as Ras can respond to GAP, the effects of the other biochemical changes would be negligible. This supports the value of a strategy that can restore GAP sensitivity to Ras mutants, and some experimental work suggests that this seemingly difficult objective may be possible (39) . However, the model simulations indicated that GAP insensitivity alone accounted for only approximately half of the increase in RasGTP, suggesting that targeting (or restoring) the other affected processes (besides GAP sensitivity) may offer a therapeutic benefit. It may prove easier to target these processes than to restore GAP-sensitivity to an oncogenic Ras mutant.
A mathematical model of a biochemical network can also be expanded to include drugs to investigate how they affect cell signaling networks (40) . As opposed to traditional wetlaboratory investigations, these studies can be done before an actual drug with these properties has been synthesized to evaluate whether the development of a particular drug would be a worthwhile endeavor (41) . One possible problem that could arise from using any Ras inhibitor is that it may result in toxicity due to the importance of Ras pathway signaling in physiologically important processes (42) . We simulated three possible strategies for inhibiting Ras to identify the drug strategies that reduce Ras signaling more in networks that contain oncogenic Ras mutants (i.e., cancerous networks) than in networks with only wild-type Ras (noncancerous networks). This investigation identified the targeting of RasGTP (31, 43 -46) as a promising strategy causing greater inhibition in the cancerous network than in the noncancerous network. Targeting both RasGDP and RasGTP (47), or targeting RasGDP only (48) , had the opposite pattern and caused a greater inhibition in the noncancerous network.
It is commonly stated that Ras drugs should target the mutant protein more than the wild-type protein to minimize toxicity on disease-free cells (49) . For example, one could imagine a compound that noncovalently binds to oncogenic Ras but does not interact with wild-type Ras. The strategy identified in our modeling, however, was an inhibitor that bound oncogenic and wild-type RasGTP with identical properties (with identical association and dissociation rate constants). But interestingly, the disease network responded more strongly to the Ras inhibitor than the wild-type network as a result of the inherently different network properties; that is, association and dissociation rate constants elsewhere in the network differ in the context of the mutant module. This shows the importance of considering the effect of a drug on the ''target signaling network'' rather than just its effect on the ''target protein'' in drug development (36) . Additionally, the three different strategies for inhibiting Ras had different effects on the network. Computational analysis may allow for the identification of which of many possible strategies for targeting a pathway result in a preferential targeting of the diseased network.
Computational models could also play a role in the direct management of patient care (41) . Personalized medicine involves treating diseases in a manner optimized for each patient. For example, the choice of drugs and dosages for a cancer patient will be made to reflect the individual's genetics (50) and also the acquired genetic changes in their cancer (51) . Personalized medicine will likely be more complex than a one-to-one relationship between a gene mutation and a drug (36, 41, 50) . It is already understood that the efficacy of a drug tailored to a specific molecular target is determined not only by the mutation status of the target (52, 53) but also by the mutation status of other proteins in the same pathway (54) . As the effect of a drug is best thought of as its effect on the network rather than on the specific protein (36) , the selection of drugs in personalized medicine will ultimately require understanding the mutation status of many components of the targeted network rather than a single targeted molecule.
A recent survey of human cancers found that a tumor averages f10 mutations that contribute to the disease, and that several hundred different genes could harbor these mutations (55) . The number of possible combinations of 10 mutations chosen from 300 possible genes is well over 10 18 . As an individual gene could have many different mutations, each potentially influencing disease outcomes as well as the ability to respond to a drug (52, 53, 56, 57) , the number of distinct genetic entities increases even further. This explosion in the number of possibilities is similar to the ''combinatorial complexity'' that occurs for receptor tyrosine kinases with multiple phosphorylation sites and multiple binding partners (58) . As a result of the complexity of cancer, it is possible that no two patients with the same cancer have the same set of contributory mutations. Although evidence-based medicine can determine average response rates to populations with similar disease and genetics, it is not possible to have such evidencebased analysis for every combination of mutations. Rather than use treatments that are optimized for the entire population of cancer patients, it may be possible to optimize treatment to a patient's mutation status with the use of computational models that are updated to reflect the patient's genetics and used to simulate the response to different treatment options.
Mathematical models of signaling networks are already useful tools for assimilating the large amounts of quantitative and semiquantitative data characterizing biochemical networks within a cell. Their analysis has provided many insights into physiologic and pathologic signaling, including novel experimental observations that were done to test model predictions.
The identification of the most promising of drug candidates for development, and the identification of treatment strategies for a given patient are just two of many potential uses for computational models. It should be noted that to a large extent the basic technologies for obtaining information needed for the model, for modeling the system, and for testing the model experimentally are already in place. It is an exciting challenge to use and further develop these resources and to see how mathematical models can affect future cancer therapies.
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